CARDIOMETRICS' FLOWIRE/FLOMAP SALES SURGE 70% TO $8.5 MIL.
This article was originally published in The Gray Sheet
Executive Summary
CARDIOMETRICS' FLOWIRE/FLOMAP SALES SURGE 70% TO $8.5 MIL. in 1993, company President and CEO Menahem Nassi told investors Jan. 10 at the Hambrecht & Quist life sciences conference in San Francisco. The two products provided all the privately held Mountain View, California-based firm's revenues during the year; 60% of the sales were from overseas markets. FloWire and FloMap generated $1 mil. in sales in the half year they were available in 1991.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.